Browsing Tag
Pfizer
128 posts
NB.1.8.1 variant triggers global COVID-19 surge amid endemic transition
NB.1.8.1 variant drives global COVID-19 surge; China, Australia report highest transmission. WHO classifies risk as low but urges continued vaccine surveillance.
JN.1 variant: Why it still dominates global COVID-19 cases in mid-2025
JN.1 remains the most dominant COVID-19 variant in mid-2025. Explore why it still leads global cases, what WHO and CDC recommend, and how vaccines are adapting.
Fall 2025 COVID booster update: FDA endorses JN.1-based vaccine as dominant LP.8.1 strain spreads
FDA backs fall 2025 COVID booster targeting LP.8.1; rollout to begin by August. New vaccine expected to offer stronger protection against dominant variants.
Glenmark Pharmaceuticals posts 12.8% revenue rise in FY25, beats market estimates
Glenmark Pharma posts â‚ą13,894 Cr profit in FY25. Explore its global growth, R&D breakthroughs, and why ISB 2001 may define its biotech future.
ACIP expands Pfizer’s ABRYSVO vaccine guidance to include at-risk adults aged 50–59
Pfizer's RSV vaccine ABRYSVO now recommended for at-risk adults aged 50–59. Learn what it means for public health and Pfizer’s expanding vaccine portfolio.
Clover Biopharmaceuticals receives FDA clearance for RSV vaccine trial, expands respiratory disease research
Clover Biopharmaceuticals advances RSV vaccine research with FDA-approved SCB-1019 trials, targeting revaccination gaps and combination immunization strategies.
China discovers new bat coronavirus HKU5-CoV-2: How serious is the threat?
A newly identified bat coronavirus, HKU5-CoV-2, has been discovered by Chinese scientists, raising concerns about animal-to-human transmission and…
Pfizer’s ADCETRIS combination regimen secures FDA approval for relapsed large B-cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s supplemental Biologics License Application (sBLA) for ADCETRIS…
FDA approves EMBLAVEO to combat complicated intra-abdominal infections with limited treatment options
The U.S. Food and Drug Administration (FDA) has granted approval for EMBLAVEO (aztreonam and avibactam), marking a significant…
Pfizer reports strong Q4 2024 earnings, reaffirms 2025 guidance amid cost-cutting strategy
Pfizer Inc. delivered strong fourth-quarter 2024 earnings, exceeding analyst expectations and demonstrating resilience in a challenging pharmaceutical market.…